199 related articles for article (PubMed ID: 32658651)
1. A Practical Overview and Reporting Strategies for Statistical Analysis of Survival Studies.
Dey T; Mukherjee A; Chakraborty S
Chest; 2020 Jul; 158(1S):S39-S48. PubMed ID: 32658651
[TBL] [Abstract][Full Text] [Related]
2. When do we need competing risks methods for survival analysis in nephrology?
Noordzij M; Leffondré K; van Stralen KJ; Zoccali C; Dekker FW; Jager KJ
Nephrol Dial Transplant; 2013 Nov; 28(11):2670-7. PubMed ID: 23975843
[TBL] [Abstract][Full Text] [Related]
3. The importance of censoring in competing risks analysis of the subdistribution hazard.
Donoghoe MW; Gebski V
BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
[TBL] [Abstract][Full Text] [Related]
4. Cumulative incidence in competing risks data and competing risks regression analysis.
Kim HT
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
[TBL] [Abstract][Full Text] [Related]
5. Deep Survival Machines: Fully Parametric Survival Regression and Representation Learning for Censored Data With Competing Risks.
Nagpal C; Li X; Dubrawski A
IEEE J Biomed Health Inform; 2021 Aug; 25(8):3163-3175. PubMed ID: 33460387
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis in public health research.
Lee ET; Go OT
Annu Rev Public Health; 1997; 18():105-34. PubMed ID: 9143714
[TBL] [Abstract][Full Text] [Related]
7. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
8. Testing the proportional hazards assumption in cox regression and dealing with possible non-proportionality in total joint arthroplasty research: methodological perspectives and review.
Kuitunen I; Ponkilainen VT; Uimonen MM; Eskelinen A; Reito A
BMC Musculoskelet Disord; 2021 May; 22(1):489. PubMed ID: 34049528
[TBL] [Abstract][Full Text] [Related]
9. Survival Analysis and Interpretation of Time-to-Event Data: The Tortoise and the Hare.
Schober P; Vetter TR
Anesth Analg; 2018 Sep; 127(3):792-798. PubMed ID: 30015653
[TBL] [Abstract][Full Text] [Related]
10. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
11. Model selection in competing risks regression.
Kuk D; Varadhan R
Stat Med; 2013 Aug; 32(18):3077-88. PubMed ID: 23436643
[TBL] [Abstract][Full Text] [Related]
12. A win ratio approach for comparing crossing survival curves in clinical trials.
Zheng S; Wang D; Qiu J; Chen T; Gamalo M
J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
[TBL] [Abstract][Full Text] [Related]
13. Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis.
Schuster NA; Hoogendijk EO; Kok AAL; Twisk JWR; Heymans MW
J Clin Epidemiol; 2020 Jun; 122():42-48. PubMed ID: 32165133
[TBL] [Abstract][Full Text] [Related]
14. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
[TBL] [Abstract][Full Text] [Related]
15. Survival studies: competing risks, immortality and censoring.
Barnett AG; Oldmeadow C; Attia JR
Med J Aust; 2018 Jun; 208(11):475-477. PubMed ID: 29902402
[No Abstract] [Full Text] [Related]
16. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
Geskus RB
Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
[TBL] [Abstract][Full Text] [Related]
17. Time-To-Event Data: An Overview and Analysis Considerations.
Le-Rademacher J; Wang X
J Thorac Oncol; 2021 Jul; 16(7):1067-1074. PubMed ID: 33887465
[TBL] [Abstract][Full Text] [Related]
18. Planning and analyzing clinical trials with competing risks: Recommendations for choosing appropriate statistical methodology.
Poythress JC; Lee MY; Young J
Pharm Stat; 2020 Jan; 19(1):4-21. PubMed ID: 31625290
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two treatments in the presence of competing risks.
Lyu J; Chen J; Hou Y; Chen Z
Pharm Stat; 2020 Nov; 19(6):746-762. PubMed ID: 32476264
[TBL] [Abstract][Full Text] [Related]
20. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
Austin PC; Fine JP
Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
